Portage Biotech (Portage Biotech) Short-Term Debt : $0.00 Mil (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Portage Biotech Short-Term Debt?

Portage Biotech's Short-Term Debt for the quarter that ended in Dec. 2023 was $0.00 Mil.

Portage Biotech's annual Short-Term Debt declined from Mar. 2021 ($1.80 Mil) to Mar. 2022 ($0.00 Mil) but then stayed the same from Mar. 2022 ($0.00 Mil) to Mar. 2023 ($0.00 Mil).

Portage Biotech Short-Term Debt Historical Data

The historical data trend for Portage Biotech's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Portage Biotech Short-Term Debt Chart

Portage Biotech Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Short-Term Debt

Get a 7-Day Free Trial

0.66

0.30

1.80

Portage Biotech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Short-Term Debt	Get a 7-Day Free Trial															-	-	-	-	-

Portage Biotech Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Portage Biotech Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Portage Biotech's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Portage Biotech (Portage Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Portage Biotech Inc (NAS:PRTG) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Clarence Thomas Building, P.O. Box 4649, Tortola, Road Town, VGB, VG1110

Website

https://www.portagebiotech.com

Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through to clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.